针对SARS冠状病毒重要蛋白的siRNA设计(英)

RNA干涉(RNA interference, RNAi)是一种特异性地导致转录后基因沉默的现象,在哺乳动物细胞中小分子干扰RNA双链体(small interfering RNA duplexes, siRNA duplexes)可以有效地诱导RNAi现象,为一些疾病的治疗开辟了新的途径.针对SARS冠状病毒(SARS coronavirus, SARS-CoV)中编码5个主要蛋白质的基因,用生物信息学的方法设计了348条候选siRNA靶标.在理论上,相应的siRNA双链体能特异地抑制SARS-CoV靶基因的表达,同时不会影响人体细胞基因的正常表达,这为进一步siRNA类药物的实验研究提供了理论基础.     

针对SARS冠状病毒重要蛋白的siRNA设计(英文)

NA干涉 (RNAinterference ,RNAi)是一种特异性地导致转录后基因沉默的现象 ,在哺乳动物细胞中小分子干扰RNA双链体 (smallinterferingRNAduplexes ,siRNAduplexes)可以有效地诱导RNAi现象 ,为一些疾病的治疗开辟了新的途径 .针对SARS冠状病毒 (SARScoronavirus ,SARS CoV)中编码 5个主要蛋白质的基因 ,用生物信息学的方法设计了3 48条候选siRNA靶标 .在理论上 ,相应的siRNA双链体能特异地抑制SARS CoV靶基因的表达 ,同时不会影响人体细胞基因的正常表达 ,这为进一步siRNA类药物的实验研究提供了理论基础     

针对leader序列的siRNA能够有效抑制SARS冠状病毒多个mRNA的表达

小干扰RNAs(siRNAs)能够有效降解具有互补序列的RNA.在SARS-CoV的基因组RNA和所有亚基因组RNA的5′端均有一段共同的leader序列,而且该leader序列在不同的病毒分离物中高度保守,因此leader序列可作为一个用于抑制SARS-CoV复制的有效靶点.研究表明,针对leader序列化学合成的siRNA和DNA载体表达的shRNA都可以有效抑制SARS-CoV mRNA的表达.Leader序列特异的siRNA或shRNA不仅可以有效抑制leader与报告基因EGFP融合基因的表达,而且还可以有效抑制leader与刺突蛋白(spikeprotein)、膜蛋白(membrane protein)和核衣壳蛋白(nucleocapsid protein)基因的融合转录产物的表达.结果表明,针对leader序列的RNA干扰可以发展成为一种抗SARS-CoV治疗的有效策略.     

SARS冠状病毒S蛋白结构预测及表达初探

利用生物信息学的工具和方法,对SARS病毒基因组中预测的S蛋白（spike protein）的编码序列进行了分析,预测了其结构特征和可能的功能域。选择其中最有可能参与受体识别及产生主要免疫原性的区域(S401～659)作为待表达区域。将通过PCR获得的此段S蛋白片段的编码序列克隆至大肠杆菌载体pET28a(+)和酵母表达载体pPIC9K中,分别构建了pET28a(+)-S和pPIC9K-S表达质粒,转化至大肠杆菌菌株BL21(DE3)-star和毕赤酵母中表达。产物的蛋白电泳和蛋白印记结果表明,S蛋白片段获得成功表达。采用镍离子螯合层析法纯化变性的包涵体样品,纯度达90%以上。     

SARS冠状病毒S蛋白的功能性受体-ACE2

SARS冠状病毒的棘突S蛋白 ,与细胞受体介导的感染有关。血管紧张素转化酶 2 (ACE2 )是SARS CoVS蛋白的功能性受体 ,人类ACE2酶的细胞外区域由 2个亚基组成 ,其中锌金属肽酶区域可以进一步分成 2个亚域 (I和II) ,形成一个长而深的裂缝 ,环绕裂缝顶端的隆起线可能作为与S 糖蛋白结合的区域。ACE2可以与SARS CoVS蛋白的S3 1 8 5 1 0结合。这将为发展新型SARS疫苗和SARS的预防和治疗提供新的研究方向。     

冠状病毒S蛋白的结构和功能

冠状病毒S蛋白具有受体结合活性和膜融合活性,在组织嗜性、细胞融合和毒力等方面具有重要作用。本综述了S蛋白的一般结构特征及其与细胞受体和膜融合的关系,并介绍了最近发现的SARS病毒S蛋白与其他冠状病毒的异同。     

严重急性呼吸综合征(SARS)冠状病毒S蛋白的鉴定与分析

利用293细胞对SARS病人样品进行病毒扩增,培养上清中病毒颗粒经过纯化后,利用蛋白质组学技术,对纯化得到的SARS冠状病毒颗粒蛋白进行初步分离与鉴定。其中质谱分析结果最终表明,分子量约150kD的蛋白质的氨基酸序列与SARS—CoV基因组所预测S蛋白质序列高度吻合,从而首次从蛋白质水平对SARS冠状病毒S蛋白的氨基酸序列进行了证实。     

SARS冠状病毒S蛋白片段2的表达纯化与多克隆抗体的制备

采用RT-PCR技术从SARS冠状病毒基因组扩增编码S蛋白的S2基因片段(第2170到2814位碱基),克隆到pMD18-T载体并测序.用限制性内切酶消化后,S2基因亚克隆至表达载体pGEX-4T-2,转化大肠杆菌JM109,筛选鉴定阳性菌落.扩增培养含pGEX-S2质粒的JM109大肠杆菌,经IPTG诱导,超声破菌,GSH-Sepharose亲和层析纯化目的蛋白,Western-blot检测SARS患者血清可以识别纯化的蛋白.用此蛋白免疫NIH小鼠,获得了高滴度抗GST-S2抗体的血清,为进一步研究SARS冠状病毒的亚单位疫苗奠定基础.     

SARS冠状病毒S蛋白片段2的表达纯化与多克隆抗体的制备

采用RTPCR技术从SARS冠状病毒基因组扩增编码S蛋白的S2基因片段(第2170到2814位碱基),克隆到pMD18T载体并测序。用限制性内切酶消化后,S2基因亚克隆至表达载体pGEX4T2,转化大肠杆菌JM109,筛选鉴定阳性菌落。扩增培养含pGEXS2质粒的JM109大肠杆菌,经IPTG诱导,超声破菌,GSHSepharose亲和层析纯化目的蛋白,Westernblot检测SARS患者血清可以识别纯化的蛋白。用此蛋白免疫NIH小鼠,获得了高滴度抗GSTS2抗体的血清,为进一步研究SARS冠状病毒的亚单位疫苗奠定基础。     

SARS冠状病毒的分子生物学研究

严重急性呼吸系统综合征(SARS)是2002年底爆发于中国广东,后蔓延全球的传染性疾病。其病原体为一种未知的新型冠状病毒,章从SARS冠状病毒的蛋白构成和功能研究、SARS冠状病毒感染机制(表型变化,受体)、SARS冠状病毒分子进化这几个方面对现有研究进展做一综述。     

Genome-wide application of RNAi to the discovery of potential drug targets

Progress is being made in the development of RNA interference-based (RNAi-based) strategies for the control of gene expression. It has been demonstrated that small interfering RNAs (siRNAs) can silence the expression of target genes in a sequence-specific manner in mammalian cells. Various groups, including our own, have developed systems for vector-mediated specific RNAi. Vector-based siRNA- (or shRNA) expression libraries directed against the entire human genome and siRNA libraries based on chemically synthesized oligonucleotides now allow the rapid identification of functional genes and potential drug targets. Use of such libraries will enhance our understanding of numerous biological phenomena and contribute to the rational design of drugs against heritable, infectious and malignant diseases.     

SARS-CoV S蛋白基因的克隆及其与VSV-G融合表达载体的构建

为了解重症急性呼吸综合征冠状病毒(SARS—CoV)表面S蛋白的受体结合功能域及其在宿主细胞上的作用受体,应用PCR技术从SARS—CoV cDNA中克隆到S蛋白的全长基因,并构建了S蛋白与疱疹性口腔炎病毒胞膜蛋白(VSV—G)融合表达载体pVSV—G‘-SG,进而为制备含有SARS—CoVS蛋白膜外区的逆转录病毒假毒粒奠定了实验基础。     

The functional motif of SARS-CoV S protein involved in the interaction with ACE2

SARS-CoV is a newly discovery pathogen causing severe acute respiratory problems. It has been established that the S protein in this pathogen plays an important rule in the adsorption and penetration of SARS-CoV into the host cell by interaction with the ACE2 receptor. To determinant which functional motif of the S protein was involved in the interaction with ACE2, seven truncated S proteins deleted from the N or C terminal were obtained by an E.coli expression system and purified by column chromatography to homogeneity. Each truncated S protein was fixed on to the well of an ELISA plate and an interaction was initiated with the ACE2 protein. The adsorption were quantified by ELISA, and the results indicated that amino acids from 388 to 496 of the S protein was responsible for the interaction with the ACE2 receptor, and the interaction could be completely disrupted by an antibody specific to these amino acids. Deletions adjacent to this domain did not appear to have a significant impact on the interaction with ACE2, suggesting that the S protein of SARS-CoV could be developed as a vaccine to prevent the spread of SARS-CoV.     

siRNA对SARS冠状病毒复制的抑制作用

为探讨siRNA在哺乳动物细胞中对SARS冠状病毒复制的抑制作用,针对BJ0 1株SARS冠状病毒复制酶基因(Pol)和刺突蛋白基因(S) ,设计4个siRNA ,并构建相应的siRNA表达载体及克隆细胞系.利用间接免疫荧光法及实时定量反转录PCR法,检测所设计的siRNA对SARS冠状病毒复制的抑制作用.结果表明,针对Pol基因的siRNA(psOe)在Vero细胞中可阻断BJ0 1株SARS病毒RNA的复制及其蛋白的表达.该结果为深入阐明SARS冠状病毒的致病机理及探讨SARS病毒防治新途径奠定了基础.     

通过RNA干涉沉默SARS病毒的研究前景

RNA干涉(RNAi)是双链RNA介导的转录后基因沉默作用的重要机制之一。RNAi在后基因组时代的基因功能研究和药物开发中具有广阔应用前景。本综述了RNAi在抗SARS病毒药物研究中的应用前景。     

SARS病毒S蛋白片段的克隆表达和纯化

以大肠杆菌表达载体pET22b为载体,直接表达SARS病毒S蛋白425-569及894-1033等2片段。表达所获得的包涵体形式蛋白经尿素溶解后分别经过2次离子交换层析,获得初步纯化。在酸性和低尿素浓度环境中,2种S蛋白片段极易沉淀。Western印迹鉴定显示其与抗SARS病毒血清呈阳性反应。获得的纯化蛋白可用于检验受体结合能力等研究。     

The Functional Motif of SARS-CoV S Protein Involved in the Interaction with ACE2

SARS-CoV is a newly discovery pathogen causing severe acute respiratory problems. It has been established that the S protein in this pathogen plays an important rule in the adsorption and penetration of SARS-CoV into the host cell by interaction with the ACE2 receptor. To determinant which functional motif of the S protein was involved in the interaction with ACE2, seven truncated S proteins deleted from the N or C terminal were obtained by an E.coli expression system and purified by column chroma-tography to homogeneity. Each truncated S protein was fixed on to the well of an ELISA plate and an interaction was initiated with the ACE2 protein. The adsorption were quantified by ELISA, and the results indicated that amino acids from 388 to 496 of the S protein was responsible for the interaction with the ACE2 receptor, and the interaction could be completely disrupted by an antibody specific to these amino acids. Deletions adjacent to this domain did not appear to have a significant impact on the interaction with ACE2, suggesting that the S protein of SARS-CoV could be developed as a vaccine to prevent the spread of SARS-CoV.     

首例RNA干扰药物问世及该领域技术演化历程

近期,RNA干扰(RNAi)制药公司Alnylam开发的小干扰RNA (siRNA)药物ONPATTRO?美国食品与药物管理局和欧盟委员会批准上市,用于治疗成人患者的遗传性转甲状腺素蛋白淀粉样变性引起的多发性神经病变.这是全球第一款RNAi药物,该事件标志着人类继小分子化合物、单克隆抗体蛋白类药物后,在前沿生物制药领域实现了新的突破,意味着RNAi疗法从基础研究到临床治疗的开发全过程首次贯通,具有里程碑式的意义.本文概述了该药物及适应症的基本情况,介绍了RNAi发现历史、作用机理与药物特征,RNAi药物的研发历程,以及该领域关键技术的最新研究进展.